Commentary: BMI and the need for adalimumab dose escalation in Crohn's disease.

The authors discuss the study conducted by E. Bultman and colleagues on the predictors of dose escalation in Crohn's disease patients treated with adalimumab. The authors say that clinical trials with infliximab and adalimumab in Crohn's disease have shown a response loss with need for dose optimization. They note that the study show 39% of 122 patients needed adalimumab dose optimization after a year. Moreover, the relation of body mass index (BMI) to adalimumab is discussed.